Rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by sequential use of nilotinib and imatinib: A GIMEMA protocol LAL 1408.
Cristina Papayannidis
No relevant relationships to disclose
Alfonso Piciocchi
No relevant relationships to disclose
Antonella Vitale
No relevant relationships to disclose
Ilaria Iacobucci
No relevant relationships to disclose
Simona Soverini
No relevant relationships to disclose
Francesco Di Raimondo
No relevant relationships to disclose
Stefania Paolini
No relevant relationships to disclose
Giovanni Pizzolo
No relevant relationships to disclose
Angelo Michele Carella
No relevant relationships to disclose
Mario Cazzola
No relevant relationships to disclose
Antonio Cuneo
No relevant relationships to disclose
Pietro Leoni
No relevant relationships to disclose
Mario Luppi
No relevant relationships to disclose
Enrica Morra
No relevant relationships to disclose
Giorgina Specchia
No relevant relationships to disclose
Loredana Elia
No relevant relationships to disclose
Robin Foa
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Michele Baccarani
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis
Honoraria - Novartis
Giovanni Martinelli
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer; Roche